'Cobiotic' Patent Application Filed

NEW ORLEANSNuMe Health LLC filed a patent application covering a proprietary formulation of its "cobiotic" product, NM504, which is being developed for the prediabetic population. NM504 is designed to help prediabetic individuals achieve and maintain normal blood glucose levels and a healthy body weight by altering the gastrointestinal (GI) microbiota and its environment. 

NuMe Health said NM504 contains a blend of ingredients that can alter the composition of the GI microbiota in specific ways that promote improved control of glucose levels for prediabetics with an unhealthy weight.  It acts by stimulating certain bacteria that inhibit appetite signals and stimulate satiety signals and also by inhibiting the ability of other bacteria to capture energy from undigested fat and protein and convert them into calories that are absorbed by the body.

The patent filing covers the composition, manufacture and delivery of NM504. 

NuMes cobiotics are designed to encourage healthy bacteria, discourage unhealthy bacteria and create a healthy GI environment.  Cobiotics are combinations of prebiotics and other food components that cannot be digested, but that act to control the GI microbiota and its environment in specific beneficial ways.  NuMe's initial cobiotic products are derived from bioactive ingredients in edible plants that promote the growth of specific beneficial bacteria with the potential to positively affect metabolic conditions.